|
|
|
|
LEADER |
01000caa a22002652c 4500 |
001 |
NLM365992496 |
003 |
DE-627 |
005 |
20250305140805.0 |
007 |
cr uuu---uuuuu |
008 |
231227s2024 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1002/adma.202309705
|2 doi
|
028 |
5 |
2 |
|a pubmed25n1219.xml
|
035 |
|
|
|a (DE-627)NLM365992496
|
035 |
|
|
|a (NLM)38108547
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Macchia, Eleonora
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Point-Of-Care Ultra-Portable Single-Molecule Bioassays for One-Health
|
264 |
|
1 |
|c 2024
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 29.03.2024
|
500 |
|
|
|a Date Revised 30.03.2024
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a © 2023 The Authors. Advanced Materials published by Wiley‐VCH GmbH.
|
520 |
|
|
|a Screening asymptomatic organisms (humans, animals, plants) with a high-diagnostic accuracy using point-of-care-testing (POCT) technologies, though still visionary holds great potential. Convenient surveillance requires easy-to-use, cost-effective, ultra-portable but highly reliable, in-vitro-diagnostic devices that are ready for use wherever they are needed. Currently, there are not yet such devices available on the market, but there are a couple more promising technologies developed at readiness-level 5: the Clustered-Regularly-Interspaced-Short-Palindromic-Repeats (CRISPR) lateral-flow-strip tests and the Single-Molecule-with-a-large-Transistor (SiMoT) bioelectronic palmar devices. They both hold key features delineated by the World-Health-Organization for POCT systems and an occurrence of false-positive and false-negative errors <1-5% resulting in diagnostic-selectivity and sensitivity >95-99%, while limit-of-detections are of few markers. CRISPR-strip is a molecular assay that, can detect down to few copies of DNA/RNA markers in blood while SiMoT immunometric and molecular test can detect down to a single oligonucleotide, protein marker, or pathogens in 0.1mL of blood, saliva, and olive-sap. These technologies can prospectively enable the systematic and reliable surveillance of asymptomatic ones prior to worsening/proliferation of illnesses allowing for timely diagnosis and swift prognosis. This could establish a proactive healthcare ecosystem that results in effective treatments for all living organisms generating diffuse and well-being at efficient costs
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Review
|
650 |
|
4 |
|a Single‐molecule with a large transistor(SiMoT)
|
650 |
|
4 |
|a clustered regularly interspaced short palindromic repeats/Cas (CRISPR/Cas)
|
650 |
|
4 |
|a lateral flow strip test
|
650 |
|
4 |
|a one health
|
650 |
|
4 |
|a point of care testing (POCT)
|
650 |
|
4 |
|a preventing healthcare
|
650 |
|
7 |
|a RNA
|2 NLM
|
650 |
|
7 |
|a 63231-63-0
|2 NLM
|
700 |
1 |
|
|a Torricelli, Fabrizio
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Caputo, Mariapia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sarcina, Lucia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Scandurra, Cecilia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bollella, Paolo
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Catacchio, Michele
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Piscitelli, Matteo
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Di Franco, Cinzia
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Scamarcio, Gaetano
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Torsi, Luisa
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 13 vom: 12. März, Seite e2309705
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:13
|g day:12
|g month:03
|g pages:e2309705
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202309705
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 36
|j 2024
|e 13
|b 12
|c 03
|h e2309705
|